ICCM - IceCure rises 300% as trial data shows ProSense safe and effective in treating Kidney tumors

• IceCure Medical ( NASDAQ: ICCM ) has risen four-folds after the company announced interim results from a study for its minimally-invasive cryoablation technology, the ProSense System that destroys tumors by freezing, to treat patients with small renal masses who cannot be offered kidney-preserving surgery.
• ProSense was found to be a safe and effective for renal lesions smaller than 5 cm in patients not suitable for kidney-preserving surgery.
• The company said in a subgroup of patients with no previous history of kidney cancer on the same kidney and a lesion ?3 cm, an 89.5% recurrence-free rate was observed at a mean follow-up time of 22.2 months.
• The recurrence-free rate was 85.1% for the 107 patients, at a mean follow-up period of 16.5 months.

For further details see: